<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>48</patient-age><report-id>PHEH2012US019041</report-id><gender>female</gender><reactions><reaction>Patient had an ECG (electrocardiogram) and the physician did not like the results</reaction><reaction>Headaches</reaction><reaction>Heart palpitation</reaction><reaction>Eyes look yellow</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>TASIGNA</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>SERTRALINE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>AMBIEN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>HYDROXYUREA</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Chronic myeloid leukaemia</indication></indications><patient-age>48</patient-age><outcomes/><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053147_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211133941</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHEH2012US019041</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="2">No</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-09-20</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-05</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHEH2012US019041</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>ND</patientinitial>
			<patientonsetage>48</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex code="2">Female</patientsex>
			<reaction>
				<primarysourcereaction>Patient had an ECG (electrocardiogram) and the physician did not like the results</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>ECG abnormal</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Electrocardiogram abnormal</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Headaches</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Headache</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Headache</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Heart palpitation</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Palpitations</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Palpitations</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120905</reactionstartdate>
				<reactionfirsttime>16</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Eyes look yellow</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Yellow ocular coloring</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Ocular icterus</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120913</testdate>
				<testname>Electrocardiogram</testname>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>TASIGNA</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>22-068</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>400</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>400 mg, BID</drugdosagetext>
				<drugdosageform normalized="capsule">Capsule</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Chronic myeloid leukaemia</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-08-21</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-09-05</drugenddate>
				<drugtreatmentduration>16</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMN107</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Electrocardiogram abnormal</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Electrocardiogram abnormal</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Headache</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Headache</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Ocular icterus</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Ocular icterus</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Palpitations</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Palpitations</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>SERTRALINE</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>SERTRALINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>AMBIEN</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ZOLPIDEM TARTRATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>HYDROXYUREA</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>HYDROXYCARBAMIDE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHEH2012US019041 is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report from a consumer (patient) via CVS Caremark <Semaphore x="2209948" class="Disease or Finding" value="Medical or Surgical Procedure Requiring Relocation of Lead" score="1.00" ID="C99983">specialty </Semaphore><Semaphore x="2394141" class="Occupation" value="Pharmacist" score="1.00" ID="C51840">pharmacy </Semaphore>received on 20 Sep 2012, with a follow up report from consumer (patient) via CVS Caremark <Semaphore x="2209948" class="Disease or Finding" value="Medical or Surgical Procedure Requiring Relocation of Lead" score="1.00" ID="C99983">speciality </Semaphore><Semaphore x="2394141" class="Occupation" value="Pharmacist" score="1.00" ID="C51840">pharmacy </Semaphore>received on 05 Dec 2012. This report refers to a 48-year old female patient. Concomitant medications included <Semaphore x="1179716" class="Medicine" value="Sertraline" score="0.49" ID="259902">sertraline</Semaphore>, <Semaphore x="92976" class="Medicine" value="Ambien" score="0.49" ID="227378">Ambien </Semaphore>(<Semaphore x="1384921" class="Medicine" value="Zolpidem tartrate" score="0.49" ID="249188">zolpidem tartrate</Semaphore>) and <Semaphore x="687729" class="Medicine" value="hydroxyurea" score="0.49" ID="270940">Hydroxyurea </Semaphore>(hydroxycarbamide). The patient received <Semaphore x="1248114" class="Medicine" value="Tasigna" score="0.87" ID="282225">Tasigna </Semaphore>(<Semaphore x="928154" class="Medicine" value="nilotinib" score="0.49" ID="278855">nilotinib</Semaphore>) for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore><Semaphore x="2861453" class="MedDRA LLT" value="Chronic myeloid leukaemia" score="1.00" ID="10009013">of <Semaphore x="2861453" class="MedDRA LLT" value="Chronic myeloid leukaemia" score="1.00" ID="10009013"><Semaphore x="1779493" class="Disease or Finding" value="Chronic Leukemia" score="1.00" ID="C3483">chronic <Semaphore x="3120003" class="MedDRA LLT" value="Myeloid leukaemia" score="1.00" ID="10028549">myeloid leukemia </Semaphore></Semaphore>without mention of <Semaphore x="2458238" class="Disease or Finding" value="Remission" score="1.00" ID="C18246">remission </Semaphore></Semaphore></Semaphore>from 21 Aug 2012 at a dose of 400 mg BID <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally</Semaphore>. On 05 Sep 2012, after starting <Semaphore x="1248114" class="Medicine" value="Tasigna" score="0.87" ID="282225">Tasigna </Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy</Semaphore>, the patient experienced <Semaphore x="2010398" class="AnatomicStructure" value="Heart" score="1.00" ID="C12727">heart </Semaphore><Semaphore x="2367329" class="Disease or Finding" value="Palpitation" score="1.00" ID="C37999">palpitations</Semaphore>. <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">Treatment </Semaphore>with <Semaphore x="1248114" class="Medicine" value="Tasigna" score="0.87" ID="282225">Tasigna </Semaphore>was discontinued by the <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>on the same day. On 13 Sep 2012, the patient had an <Semaphore x="1877067" class="Procedure" value="Electrocardiography" score="1.00" ID="C38053">ECG </Semaphore>(<Semaphore x="1877067" class="Procedure" value="Electrocardiography" score="1.00" ID="C38053">electrocardiogram</Semaphore>) and the <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>did not like the <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">results</Semaphore>. The patient was going to see cardiologist on 21 Sep 2012. On an unspecified date, the patient stated that her <Semaphore x="1917161" class="AnatomicStructure" value="Eye" score="1.00" ID="C12401">eyes </Semaphore>looked yellow and she experienced <Semaphore x="2008813" class="Disease or Finding" value="Headache" score="1.00" ID="C34661">headaches</Semaphore>. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the event <Semaphore x="2367329" class="Disease or Finding" value="Palpitation" score="1.00" ID="C37999">palpitations </Semaphore>was reported as condition <Semaphore x="1409602" class="Procedure" value="About What Time is it" score="1.00" ID="C110931">unchanged</Semaphore>. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the remaining events was not reported. The causality of the events was not reported. No further information was available.Follow up report from consumer (patient) via CVS Caremark <Semaphore x="2209948" class="Disease or Finding" value="Medical or Surgical Procedure Requiring Relocation of Lead" score="1.00" ID="C99983">speciality </Semaphore><Semaphore x="2394141" class="Occupation" value="Pharmacist" score="1.00" ID="C51840">pharmacy </Semaphore>received on 05 Dec 2012: Updated indication, <Semaphore x="1805680" class="Procedure" value="Concomitant Therapy" score="1.00" ID="C53630">therapy start date,concomitant </Semaphore><Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drugs </Semaphore>and events (<Semaphore x="1917161" class="AnatomicStructure" value="Eye" score="1.00" ID="C12401">eyes </Semaphore>look yellow and <Semaphore x="2008813" class="Disease or Finding" value="Headache" score="1.00" ID="C34661">headaches</Semaphore>).</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>